Another huge bio deal, page-35

I hope you're right because I have a lot riding on a positive outcome here.

I am not sure you understood my post or that I wrote it clearly enough.

I am not suggesting that it would be a good idea to leave Fragile X out of any deal. I was merely putting it out there that a deal allowing for the success of Fragile X might be too big a risk for a large company at this stage of NEU's development process and Dr T would have to ask too much for its inclusion in any deal, given its potential.

If you are aware of a better hypothesis as to why the deal is taking longer than any of us anticipated then I am all ears.